- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00990054
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this research study is to determine if plerixafor can make cells more sensitive to killing by cytarabine and daunorubicin, an anti-cancer drug regimen referred to as "7+3" that is commonly used in treating acute myeloid leukemia (AML). In this study, plerixafor is used with treatments cytarabine and daunorubicin and with and without granulocyte-colony stimulating factor (GCSF). Subjects will be monitored to see how well they tolerate the use of these drugs together and how well they work to treat the leukemia.
The purpose of the study is to determine the maximum tolerated dose (MTD) per plerixafor dosing schedule (once daily [QD] or twice daily [BID]), and/or recommended phase 2 dose (RP2D), by assessing safety and tolerability of plerixafor (Mozobil®) when used in combination with cytarabine and daunorubicin, and with and without granulocyte-colony stimulating factor (G-CSF)
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Michigan
-
Ann Arbor, Michigan, United States
-
-
Missouri
-
St. Louis, Missouri, United States
-
-
New York
-
Rochester, New York, United States
-
-
Ohio
-
Cleveland, Ohio, United States
-
-
Texas
-
Houston, Texas, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provide signed, dated informed consent prior to any protocol-specific procedures.
- Have a diagnosis of newly diagnosed AML, defined as >20% myeloblasts on the marrow aspirate or peripheral blood differential, with or without extramedullary involvement, with confirmatory immunophenotyping or immunocytochemistry (e.g., myeloperoxidase), documented within 14 days of enrollment.
- Have Eastern Cooperative Oncology Group (ECOG) performance status (Appendix A) score of 0, 1, or 2.
- Toxicities from all prior treatments have resolved to baseline or δ Grade 1 prior to first dose of study drugs.
- Are surgically or biologically sterile or willing to practice acceptable birth control, as follows: Females of child bearing potential must agree to abstain from sexual activity or to use a medically approved contraceptive measure/regimen during and for 3 months after the treatment period. Women of child bearing potential must have a negative serum pregnancy test at the time of enrollment. Acceptable methods of birth control include oral contraceptive, intrauterine device (IUD), transdermal/implanted or injected contraceptives and abstinence.
- Males must agree to abstain from sexual activity or agree to utilize a medially-approved contraception method during and for 3 months after the treatment period.
- Have adequate renal and hepatic function, as indicated by the following laboratory values: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) δ2.5 - upper limit of normal (ULN); Estimated creatinine clearance (CrCl) of > 50mL/min, as calculated by the Cockcroft-Gault equation (Appendix F); total bilirubin ≤1.5-ULN (except in patients with Gilbert Syndrome, in whom direct bilirubin must be ≤1.5-ULN), International Normalized Ratio (INR) ≤1.5 after discontinuation of anticoagulants.
- Have adequate cardiac function, as measured by left ventricular ejection fraction (LVEF) ≥40% on echocardiography or multigated acquisition (MUGA) scan or similar radionuclide angiographic scan.
- Be able to comply with study procedures and follow-up examinations.
Exclusion Criteria:
- Have received previous systemic treatment for leukemia or antecedent hematologic disorder (AHD), other than hydroxyurea or hematopoietic growth factors. Treatment with hydroxyurea within 2 weeks of screening is allowed but must be discontinued at least 24 hours prior to the first dose of study drugs.
- Have received prior treatment with plerixafor, cytarabine, or any anthracycline.
- Have a diagnosis of acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 or World Health Organization (WHO) classification of APL with t(15;17)(q(22;q12), or Bcr-Abl positive leukemia.
- For patients < 50 years of age, have cytogenetics associated with good prognosis [(t(8;21)q(22;22), t(15;17),inv(16)(p13;q22)]. (Testing for these mutations must be performed on blood or Bone Marrow prior to study registration.
- Have had a hematopoietic stem cell transplant (HSCT).
Have an absolute blast count of the following at the time of first dose of chemotherapy, despite cytoreduction with hydroxyurea or leukapheresis:
- >50 x 10^9/L for patients not enrolled in a G-CSF-containing cohort
- >25 x 10^9/L for patients enrolled in a G-CSF-containing cohort
- Have central nervous system (CNS) leukemia (Only patients with suspected CNS leukemia must undergo lumbar puncture.)
- Have any of the following within the last 12 months: unstable supraventricular arrhythmia (e.g., hemodynamic instability) or has a pacemaker; Any ventricular arrhythmia, other than occasional premature ventricular contractions; Congestive heart failure (controlled or uncontrolled); Myocardial infarction, ischemia, stable coronary artery disease, or angina; Uncontrolled hypertension; Syncope with either a known cardiovascular or an unknown etiology.
- Have a pre-existing disorder predisposing the patient to serious or life-threatening infection (e.g., cystic fibrosis, congenital or acquired immunodeficiency, bleeding disorder, or cytopenias).
- Have the need for anticoagulant therapy.
- Have a significant medical or psychiatric disorder that would interfere with consent, study participation, or follow-up.
- Have an active acute or chronic systemic fungal, bacterial, viral, or other infection (i.e., exhibiting ongoing signs/symptoms related to the infection [except isolated fever] and without improvement, despite appropriate antibiotics or other treatment).
- Have severe concurrent diseases (e.g., a history of serious organ dysfunction or disease) that may place the patient at undue risk to undergo induction therapy per protocol, or obscure assessments of drug safety.
Have a diagnosis of prior malignancy unless disease-free for at least 5 years following therapy with curative intent, with the following exceptions:
- Patients with treated nonmelanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, if definitive treatment for the condition has been completed; or
- Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) values after treatment with curative intent.
- Have known human immunodeficiency virus (HIV) positivity or evidence of active viral hepatitis.
- Are pregnant or breastfeeding.
- Are known to have an allergy to any component of the study drug regimen
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: plerixafor
|
240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the maximum tolerated dose of plerixafor when used in combination with cytarabine and daunorubicin and with and without GCSF
Time Frame: 28 days from first dose and up to 42 days following last dose
|
28 days from first dose and up to 42 days following last dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Anti-leukemia activity of plerixafor when used with cytarabine and daunorubicin
Time Frame: Beginning at Day 14 and then until complete remission (CR), complete remission with incomplete count recovery (CRi), or treatment failure (TF)
|
Beginning at Day 14 and then until complete remission (CR), complete remission with incomplete count recovery (CRi), or treatment failure (TF)
|
Maximal plasma concentration (Cmax) of plerixafor when used with cytarabine and daunorubicin
Time Frame: Cycle 1 (1 week)
|
Cycle 1 (1 week)
|
Time to maximal plasma concentration (Tmax) of Plerixafor when used with cytarabine and daunorubicin
Time Frame: Cycle 1 (1 week)
|
Cycle 1 (1 week)
|
Area under the concentration-time curve from time zero to the last observed concentration (AUC 0-last) of plerixafor when used with cytarabine and daunorubicin
Time Frame: Cycle 1 (1 week)
|
Cycle 1 (1 week)
|
Area under the concentration-time curve over the dosing interval (τ) (AUC 0-τ) of plerixafor when used with cytarabine and daunorubicin
Time Frame: Cycle 1 (1 week)
|
Cycle 1 (1 week)
|
Area under the concentration-time curve from time zero to infinity (AUC 0-∞ ) of plerixafor when used with cytarabine and daunorubicin
Time Frame: Cycle 1 (1 week)
|
Cycle 1 (1 week)
|
Half-life (T½) of plerixafor when used with cytarabine and daunorubicin
Time Frame: Cycle 1 (1 week)
|
Cycle 1 (1 week)
|
Volume of distribution (Vz/F for SC administration; Vz for IV administration); in the case of multiexponential disposition, volume of distribution at steady-state (Vss) will be calculated of plerixafor when used with cytarabine and daunorubicin
Time Frame: Cycle 1 (1 week)
|
Cycle 1 (1 week)
|
Obtain preliminary data on safety , tolerability, PK, leukemia cell mobilization and anti-leukemia activity of plerixafor when used in conjunction with G-CSF, cytarabine and daunorubicin.
Time Frame: Cycle 1 (1 week) and then until complete remission (CR), complete remission with incomplete count recovery (CRi), or treatment failure (TF)
|
Cycle 1 (1 week) and then until complete remission (CR), complete remission with incomplete count recovery (CRi), or treatment failure (TF)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MOZ04808
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
Clinical Trials on Plerixafor
-
National Heart, Lung, and Blood Institute (NHLBI)Completed
-
Stephen CoubanGenzyme, a Sanofi CompanyCompletedMalignant Lymphoma, Stem Cell TypeCanada
-
Kyowa Kirin Co., Ltd.CompletedMultiple Myeloma and Malignant LymphomaJapan
-
University of WashingtonCompleted
-
Genzyme, a Sanofi CompanySanofiCompletedNeuroblastoma | Brain Tumors | Ewing's Sarcoma/Soft Tissue SarcomaBelgium, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Spain, United Kingdom
-
University Hospital, Clermont-FerrandCompletedChildren Cancer, Solid TumorFrance
-
National Institute of Allergy and Infectious Diseases...Lombardi Comprehensive Cancer CenterTerminated
-
Genzyme, a Sanofi CompanyCompletedRenal ImpairmentUnited States
-
SanofiCompletedAutologous Haematopoietic Stem Cell TransplantChina